Working… Menu

Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months (NiCOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03298893
Recruitment Status : Active, not recruiting
First Posted : October 2, 2017
Last Update Posted : October 6, 2020
Bristol-Myers Squibb
Information provided by (Responsible Party):
Institut Curie

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : October 30, 2020
Estimated Study Completion Date : September 15, 2022